Generic Name and Formulations:
Trimethoprim 100mg, 200mg; tabs.
Various generic manufacturers
Indications for Trimethoprim:
Treatment of initial episodes of uncomplicated UTI due to susceptible strains (E. coli, P. mirabilis, K. pneumoniae, Enterobacter species, coagulase-negative Staphylococcus species, including S. saprophyticus).
Treat for 10 days. 100mg every 12 hours or 200mg every 24 hours. CrCl 15–30mL/min: 50mg every 12 hours. CrCl<15mL/min: not recommended.
Megaloblastic anemia due to folate deficiency.
May interfere with hematopoieses (esp. when given in large doses and/or prolonged periods). Obtain CBCs if signs of serious blood disorder develop, discontinue if significant reduction in any formed blood element is found. Possible folate deficiency. Renal or hepatic impairment. Pregnancy (Cat.C). Nursing mothers.
Folic acid inhibitor.
May potentiate phenytoin. May interfere with serum methotrexate assay, Jaffe alkaline picrate reaction assay for creatinine.
Rash, pruritus, GI upset, blood dyscrasias, hyperkalemia, hyponatremia, fever, increased BUN, serum creatinine; rare: aseptic meningitis, cholestatic jaundice, hypersensitivity reactions.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline